Folia Medica Indonesiana
ISSN 0303-7932
Vol. 50 / No. 3 / Published : 2014-07
Order : 8, and page :172 - 178
Related with : Scholar Yahoo! Bing
Original Article :
Magnesium and potassium parenteral supplementation does not produce significant effect on magnesium and potassium serum level of cervical cancer patients receiving cisplatin chemotherapy
Author :
- Elisabeth Kasih*1
- Suhatno*2
- Yulistiani*3
- Muhammad Yahya*4
- Dosen Fakultas Kedokteran
- Dosen Fakultas Kedokteran
- Dosen Fakultas Farmasi
- Pharmacy Unit, Dr. Soetomo Hospital, Surabaya
Abstract :
Cisplatin is a chemotherapeutic agent for cervical cancer patients receiving radiation as the main therapy. One of cisplatin’s sideeffects is electrolyte disturbance, which is decreasing magnesium and potassium level. However, the application of MgSO4 and KClparenteral supplementation effectiveness as the hypomagnesaemia and hypokalemia prophylaxis remained in question. This studywas to evaluate magnesium and potassium parenteral supplementation effectiveness on magnesium and potassium serum level incervical cancer patients receiving cisplatin 50 mg/m2. This was an observational study using cross-sectional method. The inclusioncriteria was IIB stage cervical cancer patients who were going to receive the fourth cycle. All patients (n=22 patients) received 1000cc normal saline (NS) hydration, but only patients in treatment group (n=11 patients) received MgSO4 (0.5 g) and KCl (10 mEq)supplementation together with post-chemotherapy hydration. Data obtained were magnesium, potassium, creatinine, and BUN serumconcentration, each was measured pre- and post-fourth cycle cisplatin chemotherapy. Results, in pre-fourth cycle control group,magnesium serum level was 1.87 ± 0.22 mg/dL while potassium was 4.15 ± 0.71 mmol/L. In post-fourth cycle, magnesium serum was1.75 ± 0.19 mg/dL while potassium was 4.21 ± 0.67 mmol/L. In pre-fourth cycle treatment group, magnesium serum was 1.95 ± 0.25mg/dL while potassium was 4.06 ± 0.36 mmol/L. In post-fourth cycle, magnesium serum was 1.85 ± 0.16 mg/dL while potassium was4.01 ± 0.28 mmol/L. In conclusions, both groups showed no significant difference in magnesium serum and in potassium levels. Noclinical manifestation hypomagnesaemia or hypokalemia appeared in any patient. (FMI 2014;50:172-178)
Keyword :
cisplatin, electrolyte disturbances, magnesium serum, potassium serum, supplementation,
References :
Anvari K, Toussi MS, Mirsadraee M,(2010) Evaluation of intravenous magnesium supplementation as prophylaxis for cisplatin-induced hypomagnesemia 1, 109-114 : Middle East J Cancer
Arunkumar PA, Mukund H, Radheshyam N, Belliyappa MS,(2011) Clinical evaluation of cisplatin induced nephrotoxicity characterized by electrolyte disturbances 1, 100-104 : Asian J Res Pharm Sci
Archive Article
Cover Media | Content |
---|---|
![]() Volume : 50 / No. : 3 / Pub. : 2014-07 |
|